AADC Gene Therapy for Parkinson's Disease

The purpose of this study is to test the safety and tolerability of the transfer of a gene, AADC (aromatic amino acid decarboxylase) into the brains of people with moderately advanced Parkinson’s disease. In this study, the AADC gene will be delivered to a specific area of the brain and it may increase dopamine production in the brain. It is the third study of its kind. The study will also assess the effect of the treatment on clinical tests, such as mobility. 

Study participation requires 18 visits over a three year period and a surgical procedure during which the study drug will be delivered into the brain.   


1.    Diagnoses of Parkinson's disease for at least five years.

2.    Patients must be between the ages of 40 and 70

3.    Must be willing to undergo surgical procedure

4.    Patients must have been treated with levodopa for at least five years and fluctuate between the on and off state.



Marin Thompson, Study Coordinator

(415) 353-9666


[email protected]